These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 7873955)

  • 1. Events per person year--a dubious concept.
    Windeler J; Lange S
    BMJ; 1995 Feb; 310(6977):454-6. PubMed ID: 7873955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethics of placebo in studies with fracture end points in osteoporosis.
    Stein CM; Ray WA
    N Engl J Med; 2010 Sep; 363(14):1367-70; discussion e21. PubMed ID: 20879888
    [No Abstract]   [Full Text] [Related]  

  • 3. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risedronate for the prevention of fractures in postmenopausal osteoporosis.
    Sickels JM; Nip CS
    Ann Pharmacother; 2002 Apr; 36(4):664-70. PubMed ID: 11918518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial.
    Lufkin EG; Sarkar S; Kulkarni PM; Ciaccia AV; Siddhanti S; Stock J; Plouffe L
    Curr Med Res Opin; 2004 Mar; 20(3):351-7. PubMed ID: 15025844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells GA; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD001155. PubMed ID: 18253985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.
    Marcus R; Wong M; Heath H; Stock JL
    Endocr Rev; 2002 Feb; 23(1):16-37. PubMed ID: 11844743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.
    Adachi JD
    Can Fam Physician; 1998 Feb; 44():327-32. PubMed ID: 9512836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogates for fracture endpoints in clinical trials.
    Khosla S
    J Bone Miner Res; 2003 Jun; 18(6):1146-9. PubMed ID: 12817773
    [No Abstract]   [Full Text] [Related]  

  • 11. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 12. Denosumab, osteoporosis, and prevention of fractures.
    Blackwood J
    N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950411
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.
    Karpf DB; Shapiro DR; Seeman E; Ensrud KE; Johnston CC; Adami S; Harris ST; Santora AC; Hirsch LJ; Oppenheimer L; Thompson D
    JAMA; 1997 Apr; 277(14):1159-64. PubMed ID: 9087473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugs for prevention and treatment of postmenopausal osteoporosis.
    Treat Guidel Med Lett; 2005 Oct; 3(38):69-74. PubMed ID: 16177651
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL; Wan SL
    Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Estrogens for treatment of osteoporoses].
    Higuchi T; Tarakida A; Abe K; Mizunuma H
    Nihon Rinsho; 2009 May; 67(5):954-9. PubMed ID: 19432116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous broad protection against osteoporotic fractures with strontium ranelate.
    Ferrari S
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv20-4. PubMed ID: 19783590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoride and bone--quantity versus quality.
    Lindsay R
    N Engl J Med; 1990 Mar; 322(12):845-6. PubMed ID: 2308618
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prevention of osteoporotic fractures].
    Kannus P
    Duodecim; 1999; 115(7):759-64. PubMed ID: 11859509
    [No Abstract]   [Full Text] [Related]  

  • 20. Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
    Boonen S; Klemes AB; Zhou X; Lindsay R
    J Am Geriatr Soc; 2010 Apr; 58(4):658-63. PubMed ID: 20345865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.